Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Warrant (NQ: ROIVW )

N/A UNCHANGED
Last Price Updated: 3:45 PM EDT, Sep 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Warrant

< Previous 1 2 Next >
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
From Roivant Sciences
Via GlobeNewswire
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
PVTX-321 and PVTX-405 Achieve Development Candidate Nomination 
From Roivant Sciences
Via GlobeNewswire
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Change to its Board of Directors
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Proposed Public Offering of Common Shares
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker
From Roivant Sciences
Via GlobeNewswire
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Proposed Public Equity Offering
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences
From Roivant Sciences
Via GlobeNewswire
WEJO Stock: 8 Things to Know as Palantir-Backed Wejo Starts Trading Today
Wall Street is getting ready for the WEJO stock IPO as a new company enters the EV race. What should investors be watching for? 
Via InvestorPlace
Topics Electric Vehicles Initial Public Offering
Exposures Electric Vehicles Securities Market
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.